Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 2NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 3Recurrence 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
darlin protein, Dictyostelium × Clear all
NCT03180736 2025-12-19

EMN14

European Myeloma Network B.V.

Phase 3 Completed
304 enrolled 19 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT06455748 2024-06-12

Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study

First Affiliated Hospital of Wenzhou Medical University

Phase NA Recruiting
20 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03450057 2024-03-29

DARE

Hellenic Society of Hematology

Phase 2 Completed
38 enrolled 16 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT03481556 2022-12-19

ANCHOR

Oncopeptides AB

Phase 1/2 Terminated
56 enrolled 22 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡